Focused On-demand Library for Amino acid transporter heavy chain SLC3A2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P08195

UPID:

4F2_HUMAN

Alternative names:

4F2 cell-surface antigen heavy chain; 4F2 heavy chain antigen; Lymphocyte activation antigen 4F2 large subunit; Solute carrier family 3 member 2

Alternative UPACC:

P08195; J3KPF3; Q13543

Background:

The Amino acid transporter heavy chain SLC3A2, known for its roles as a chaperone in biogenesis and trafficking of functional transporter heterodimers, is crucial in cellular amino acid exchange. It forms heterodimers with SLC7 family transporters, facilitating the uptake and exchange of various amino acids across the plasma membrane. This protein is also implicated in viral infections, acting as a receptor for hepatitis C virus and Plasmodium vivax, contributing to their pathogenesis.

Therapeutic significance:

Understanding the role of Amino acid transporter heavy chain SLC3A2 could open doors to potential therapeutic strategies, especially in targeting viral infections like hepatitis C and malaria, by disrupting the protein's interaction with pathogens.